Digital Reasoning Offers Oncology Programs Leading AI Solution at Cost Now When Health Systems and Their Cancer Patients Need Help the Most
September 17, 2020 08:00 ET
|
Digital Reasoning Systems, Inc.
NASHVILLE, Tenn., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Digital Reasoning, the global leader in artificial intelligence solutions that understand human communications and behaviors, announced today...
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
August 06, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
July 21, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Rafafel_Pharma_PHP_Graphic_Updated_V3 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer...
Digital Reasoning’s AI Helps Healthcare Providers Avoid Post-COVID Wave of Preventable Cancer Deaths
May 01, 2020 08:15 ET
|
Digital Reasoning Systems, Inc.
NASHVILLE, Tenn., May 01, 2020 (GLOBE NEWSWIRE) -- Governments, healthcare providers, and others are taking extraordinary measures worldwide to contain and treat COVID-19. However, as an unintended...
MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
April 28, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, April 28, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer
March 03, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, March 03, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
January 21, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today its...
Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
January 13, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos
December 03, 2019 09:00 ET
|
Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Clinical Oncology Next-generation Sequencing Market Pegged for Robust Expansion of 17.0% CAGR by 2029 - Future Market Insights
May 20, 2019 08:30 ET
|
Future Market Insights
VALLEY COTTAGE, N.Y. , May 20, 2019 (GLOBE NEWSWIRE) -- Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology...